Pucotenlimab and Anlotinib in Combination With Chemotherapy

A prospective, multicenter, single-arm clinical study enrolling patients with histologically confirmed invasive carcinoma, clinical stage II-III, known PD-L1 status, and treatment-naïve triple-negative breast cancer. Patients will receive neoadjuvant therapy with pucotenlimab, anlotinib, and nab-paclitaxel, sequentially followed by epirubicin and cyclophosphamide, for a total of 8 cycles.

Trial Details

NCT ID
NCT07896668
Phase
PHASE2
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • LP
Locations (sample)
  • Hangzhou, China|30.29365,120.16142

Key Eligibility Criteria

  • Voluntary participation and signed informed consent.
  • Age ≥ 18 years, male or female.
  • Histologically confirmed invasive breast carcinoma with documented ER-negative, PR-negative, and HER2-negative status, defined as:
  • ER and PR: nuclear staining \< 10% by IHC;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →